(Reuters) – Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from six to 11 years of age in two late-stage studies.

The drug, SPN-812, is a non-stimulant and belongs to the same class of medicine as Eli Lilly and Co’s Strattera and Shire Plc’s Intuniv.

Analysts, however, believe that SPN-812 could have a slight advantage if it takes effect

Read More At Article Source | Article Attribution